

CMP: 1,902.90

INDEX DETAILS	
SENSEX	80,005.04
NIFTY (S&P CNX)	24339.15

(Source: Capitaline, [Investing.com](https://www.investing.com))


SCRIP DETAILS	
Industry	Pharmaceuticals
Mkt Cap (Rs in Crore)	429361.00
Book Value (Rs)	288.06
Free Float (%)	45.52
Avg Vol Weekly (NSE)	1462182
52 Week H/L (NSE)	1960 / 1209
Dividend Yield (%)	0.75
BSE Code	524715
NSE Code	SUNPHARMA

(Source: [Investing.com](https://www.investing.com))

SHAREHOLDING PATTERN (%)		
PARTICULARS	LATEST QUARTER	PREVIOUS QUARTER
Promoters	54.48	54.48
FIIIs	18.02	17.23
DIIIs	17.08	17.74
Others	10.42	10.55
Totals	100	100

(Source: Capitaline)

Price Comparison with Nifty



OPM jumped by 356 bps

On consolidated basis

Quarter ended September 2024 compared with Quarter ended September 2023

Net sales (including other operating income) of Sun Pharmaceutical Industries has increased 9.01% to Rs 13291.39 crore. Operating profit margin has jumped from 26.08% to 29.64%, leading to 23.89% rise in operating profit to Rs 3,938.96 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 13.79% to 12.50%. Purchase of finished goods cost fell from 8.34% to 6.67%. Employee cost decreased from 19.58% to 18.90%. Other expenses fell from 31.97% to 31.89%.

Other income rose 20.57% to Rs 354 crore. PBIDT rose 23.61% to Rs 4292.96 crore. Provision for interest rose 40.33% to Rs 69.17 crore. Loan funds rose to Rs 2,571.95 crore as of 30 September 2024 from Rs 1,928.23 crore as of 30 September 2023. Inventories declined from Rs 9,956.41 crore as of 30 September 2023 to Rs 9,935.65 crore as of 30 September 2024. Sundry debtors were higher at Rs 12,941.99 crore as of 30 September 2024 compared to Rs 11,302.65 crore as of 30 September 2023. Cash and bank balance rose to Rs 9,015.00 crore as of 30 September 2024 from Rs 7,222.01 crore as of 30 September 2023. Investments rose to Rs 17,743.71 crore as of 30 September 2024 from Rs 12,868.35 crore as of 30 September 2023.

PBDT rose 23.37% to Rs 4223.79 crore. Provision for depreciation fell 1.09% to Rs 625.91 crore. Fixed assets increased to Rs 20,696.74 crore as of 30 September 2024 from Rs 11,118.54 crore as of 30 September 2023. Intangible assets declined from Rs 17,790.58 crore to Rs 8,771.19 crore.

Profit before tax grew 28.92% to Rs 3,597.88 crore. Provision for tax was expense of Rs 567.21 crore, compared to Rs 390.1 crore. Effective tax rate was 15.74% compared to 14.06%.

Net profit attributable to owners of the company increased 27.98% to Rs 3,040.16 crore.

Equity capital stood at Rs 239.93 crore as of 30 September 2024 to Rs 239.93 crore as of 30 September 2023. Per share face Value remained same at Rs 1.00.

Promoters' stake was 54.48% as of 30 September 2024, compared to 54.48% as of 30 September 2023. Promoters pledged stake was 0.79% as of 30 September 2024, compared to 2.44% as of 30 September 2023.

For year-to-date (YTD) results analysis

Net sales (including other operating income) of Sun Pharmaceuticals Industries has increased 7.50% to Rs 25944.14 crore. Operating profit margin has jumped from 26.98% to 29.09%, leading to 15.90% rise in operating profit to Rs 7,546.58 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 14.79% to 12.46%. Purchase of finished goods cost rose from 7.09% to 7.30%. Employee cost decreased from 20.03% to 19.23%. Other expenses rose from 30.73% to 31.57%.

Other income rose 78% to Rs 886.55 crore. PBIDT rose 20.32% to Rs 8433.13 crore. Provision for interest rose 0.41% to Rs 130.71 crore. Loan funds rose to Rs 2,571.95 crore as of 30 September 2024 from Rs 1,928.23 crore as of 30 September 2023. Inventories declined from Rs 9,956.41 crore as of 30 September 2023 to Rs 9,935.65 crore as of 30 September 2024. Sundry debtors were higher at Rs 12,941.99 crore as of 30 September 2024 compared to Rs 11,302.65 crore as of 30 September 2023. Cash and bank balance rose to Rs 9,015.00 crore as of 30 September 2024 from Rs 7,222.01 crore as of 30 September 2023. Investments rose to Rs 17,743.71 crore as of 30 September 2024 from Rs 12,868.35 crore as of 30 September 2023 .

PBDT rose 20.69% to Rs 8302.42 crore. Provision for depreciation fell 0.24% to Rs 1281.04 crore. Fixed assets increased to Rs 20,696.74 crore as of 30 September 2024 from Rs 11,118.54 crore as of 30 September 2023. Intangible assets declined from Rs 17,790.58 crore to Rs 8,771.19 crore.

Profit before tax grew 25.50% to Rs 7,021.38 crore. Share of profit/loss was 82.31% higher at Rs -4.08 crore. Provision for tax was expense of Rs 1119.46 crore, compared to Rs 858.2 crore. Effective tax rate was 15.95% compared to 16.35%.

Net profit attributable to owners of the company increased 33.60% to Rs 5,875.78 crore.

Equity capital stood at Rs 239.93 crore as of 30 September 2024 to Rs 239.93 crore as of 30 September 2023. Per share face Value remained same at Rs 1.00.

Promoters' stake was 54.48% as of 30 September 2024, compared to 54.48% as of 30 September 2023 . Promoters pledged stake was 0.79% as of 30 September 2024, compared to 2.44% as of 30 September 2023 .

Cash flow from operating activities increased to Rs 6,299.15 crore for YTD ended September 2024 from Rs 5,718.66 crore for YTD ended September 2023. Cash flow used in acquiring fixed assets during the YTD ended September 2024 stood at Rs 697.50 crore, compared to Rs 957.72 crore during the YTD ended September 2023.

Full year results analysis

Net sales (including other operating income) of Sun Pharmaceuticals Industries has increased 10.51% to Rs 48496.85 crore. Operating profit margin has jumped from 26.54% to 26.85%, leading to 11.82% rise in operating profit to Rs 13,023.13 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 17.45% to 14.32%. Purchase of finished goods cost fell from 8.01% to 7.19%. Employee cost increased from 18.61% to 19.56%. Other expenses rose from 29.80% to 31.91%.

Other income rose 113.42% to Rs 1354.19 crore. PBDIT rose 17.07% to Rs 14377.32 crore. Provision for interest rose 38.65% to Rs 238.47 crore. Loan funds declined from Rs 6,885.87 crore as of 31 March 2023 to Rs 3,273.67 crore as of 31 March 2024. Inventories declined from Rs 10,513.05 crore as of 31 March 2023 to Rs 9,868.29 crore as of 31 March 2024. Sundry debtors were lower at Rs 11,249.37 crore as of 31 March 2024 compared to Rs 11,438.51 crore as of 31 March 2023. Cash and bank balance rose to Rs 10,520.68 crore as of 31 March 2024 from Rs 5,770.29 crore as of 31 March 2023. Investments rose to Rs 15,025.77 crore as of 31 March 2024 from Rs 14,824.34 crore as of 31 March 2023 .

PBDT rose 16.76% to Rs 14138.85 crore. Provision for depreciation rose 1.08% to Rs 2556.64 crore. Fixed assets declined from Rs 20,680.57 crore as of 31 March 2023 to Rs 19,966.31 crore as of 31 March 2024. Intangible assets increased from Rs 8,358.03 crore to Rs 8,598.95 crore.

Profit before tax grew 20.90% to Rs 11,582.21 crore. Share of profit/loss was 19.81% higher at Rs -38.41 crore. Extraordinary items were decreased to Rs -494.32 crore. Provision for tax was expense of Rs 1439.45 crore, compared to Rs 847.59 crore. Effective tax rate was 13.03% compared to 9.05%.

Minority interest decreased 14.51% to Rs 33.65 crore. Net profit attributable to owners of the company increased 13.01% to Rs 9,576.38 crore.

Equity capital stood at Rs 239.93 crore as of 31 March 2024 to Rs 239.93 crore as of 31 March 2023. Per share face Value remained same at Rs 1.00.

Promoters' stake was 54.48% as of 31 March 2024 ,compared to 54.48% as of 31 March 2023 . Promoters pledged stake was 2.05% as of 31 March 2024 ,compared to 1.78% as of 31 March 2023 .

Cash flow from operating activities increased to Rs 12,134.98 crore for year ended March 2024 from Rs 4,959.33 crore for year ended March 2023. Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 2,201.81 crore, compared to Rs 2,085.58 crore during the year ended March 2023.

Other Highlights

In Q2 FY25, India formulation sales went up 11% compared to Q2 FY24. US formulation sales grew 20.3%, Emerging Markets formulation sales up 3.2%, Global Specialty sales increased 19.2%, and Rest of World formulation sales went down 3.5% on YoY basis.

In H1 FY25, India formulation sales went up 13.6% compared to H1 FY24. US formulation sales grew 9.1%, Emerging Markets formulation sales up 5.9%, and Rest of World formulation sales went down 3.2% on YoY basis.

In Q2 FY25, external sales of API stood at Rs 533.8 crore, up by 7.4% YoY.

R&D investments stood at Rs 792.9 crore in Q2 FY25.

Management Comments:

Dilip Shanghvi, Chairman and Managing Director of the Company said, “Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercializing late stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market.”

Consolidated Results

Particulars	Quarter ended			Year to Date			Year ended		
	Q2FY25	Q3FY24	Var. (%)	H1FY25	H1FY24	Var. (%)	FY24	FY23	Var. (%)
Net Sales (including other operating income)	13,291.39	12,192.41	9.01	25,944.14	24,133.25	7.5	48,496.85	43,885.68	10.51
OPM (%)	29.64	26.08	356 bps	29.09	26.98	211 bps	26.85	26.54	31 bps
OP	3,938.96	3,179.38	23.89	7,546.58	6,511.15	15.9	13,023.13	11,646.79	11.82
Other Inc.	354	293.61	20.57	886.55	498.05	78	1,354.19	634.52	113.42
PBIDT	4,292.96	3,472.99	23.61	8,433.13	7,009.20	20.32	14,377.32	12,281.31	17.07
Interest	69.17	49.29	40.33	130.71	130.17	0.41	238.47	172	38.65
PBDT	4,223.79	3,423.70	23.37	8,302.42	6,879.03	20.69	14,138.85	12,109.31	16.76
Depreciation	625.91	632.82	-1.09	1281.04	1284.14	-0.24	2556.64	2529.43	1.08
PBT	3,597.88	2,790.88	28.92	7021.38	5594.89	25.5	11582.21	9579.88	20.9
Share of Profit/(Loss) from Associates	6.66	-15.68	LP	-4.08	-23.07	82.31	-38.41	-47.9	19.81
PBT before EO	3604.54	2775.2	29.88	7017.3	5571.82	25.94	11543.8	9531.98	21.11
EO Income	0	0	-	0	-322.87	-	-494.32	-171.45	-188.3
PBT after EO	3604.54	2775.2	29.88	7017.3	5248.95	33.69	11049.48	9360.53	18.04
Taxation	567.21	390.1	45.4	1119.46	858.2	30.44	1439.45	847.59	69.83
PAT	3037.33	2385.1	27.35	5897.84	4390.75	34.32	9610.03	8512.94	12.89
Minority Interest (MI)	-2.83	9.59	LP	22.06	-7.3	PL	33.65	39.36	-14.51
Net profit	3040.16	2375.51	27.98	5875.78	4398.05	33.6	9576.38	8473.58	13.01
P/(L) from discontinued operations net of tax	0	0	-	0	0	-	0	0	-
Net profit after discontinued operations	3040.16	2375.51	27.98	5875.78	4398.05	33.6	9576.38	8473.58	13.01
EPS (Rs)*	12.67	9.9	27.98	24.49	19.46	25.85	41.7	35.96	15.95

(Source: [NSE](#))

DISCLAIMER

This Document has been prepared by Capital Market Publishers India Pvt. Ltd. (the company) and is being distributed in India by Shriram Insight Share Brokers Limited (hereinafter referred to as "SISBL"). This document is not, and should not be construed, as an offer to sell or solicitation to buy any securities. This document may not be reproduced, distributed or published, in whole or in part, without prior permission from the Company. SISBL does not guarantee that the document is complete or accurate and it should not be relied on as such. Investors should make his/her own research, analysis and investigation as he/she deems fit and reliable to come at an independent evaluation of an investment (including the merits, demerits and risks involved), and should further take opinion of their own consultants, advisors to determine the advantages and risks of investment. SISBL, its affiliates, group companies, directors, employees, agents or representatives shall not be held responsible, liable for any kind of consequential damages whether direct, indirect, special or consequential including but not limited to lost revenue, lost profits, notional losses that may arise from or in connection with the use of the information in the document.

Shriram insight Share Brokers Limited. SEBI Reg. No. : NSE-CM [INB 230947033] | BSE-CM [INB 010947035] | NSE-F&O [INF 230947033] | NSE _CDS [INE231348633] Main Office : Ck-15, Sector-II, Salt Lake City,Kolkata-700091.

EQUITIES | DERIVATIVES | COMMODITIES | DP SERVICES | MUTUAL FUNDS | RESEARCH

SHRIRAM INSIGHT SHARE BROKERS LTD. | SEBI Reg. No. : NSE-CM [INB 230947033] | BSE-CM [INB 010947035] | NSE-F&O [INF 230947033] | NSE _CDS [INE231348633] | Main Office: CK-5, Sector-II, Saltlake City, Kolkata - 700091 | Tel : 2359 4612, 2359 4614, 2359 4877 | Fax : (033) 2321-8429 | E-mail : research@shriraminsight.com | www.shriraminsight.com |